January and February have brought significant activity on the pharmacy benefit reform front at the federal level—a long time in coming, but it is not yet time to celebrate. Read More ›

As we approach 2026, the landscape of physician reimbursement and care delivery will not be business as usual. Between new legislation, major updates to the Medicare Physician Fee Schedule (PFS), and rapid advances in artificial intelligence (AI) and care technology, healthcare delivery is entering a period of significant transition. Read More ›

The median progression-free survival was 11.14 months with ivonescimab and 5.85 months with pembrolizumab (Hazard Ratio [HR], 0.51; 95% CI, 0.38-0.69; P NSCLC, and patients with brain metastases.  Read More ›

An important and inspiring documentary on Dr Carl June’s quest to cure cancer, CAR T-cell therapy, and his first pediatric patient. Read More ›

On September 26, 2023, the FDA approved a new indication for bosutinib (Bosulif; Pfizer), a tyrosine kinase inhibitor, for the treatment of chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia in pediatric patients aged ≥1 years who are newly diagnosed or who are intolerant of or whose disease is resistant to previous therapy. A new capsule dosage form was also FDA approved, in 50-mg and 100-mg strengths; bosutinib was previously available only in 100-mg, 400-mg, and 500-mg tablet forms. The FDA granted this approval priority review and an orphan drug designation. Read More ›

On September 14, 2023, the FDA approved new and updated indications for temozolomide (Temodar; Merck) capsules and injection, an alkylating drug, including for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma, and for the treatment of adults with refractory anaplastic astrocytoma. The previously approved indication for the treatment of adults with newly diagnosed glioblastoma, concomitant with radiotherapy, then as maintenance treatment, remains unchanged. Read More ›

Peer-to-peer (PTP) support is an important aspect of nonprofessional patient care that improves cancer-specific quality of life. However, PTP research is sorely lacking, with very few randomized controlled trials being conducted in this space, as well as a lack of standardized quality parameters for what constitutes successful and efficient PTP support, according to newly published research. Read More ›